Uveal melanoma arises from melanocytes located in the uveal tract of the eye and is the most common primary intraocular tumor in adults. Metastatic liver disease is the overwhelming cause of death in uveal melanoma patients, with almost 50% of patients developing liver metastases up to 15 years after diagnosis. Most of these patients do not present with any evidence of overt metastasis at the time of initial diagnosis although it is assumed that they have undetectable micrometastases. Currently, there are no therapeutic modalities to prevent or efficiently treat the metastatic disease in uveal melanoma patients. Recent discoveries have shed light on the molecular pathways that may contribute to the progression of liver metastasis. The aim of this review is to describe new insights into the genetic and molecular pathways that may play a role in the development of liver metastases in uveal melanoma patients.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2630DOI Listing

Publication Analysis

Top Keywords

uveal melanoma
20
molecular pathways
12
melanoma patients
12
liver metastasis
8
liver metastases
8
patients
6
uveal
6
liver
5
melanoma
5
pathways mediating
4

Similar Publications

Global incidence and prevalence in uveal melanoma.

Adv Ophthalmol Pract Res

October 2024

Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Purpose: The most common intraocular cancer in adults is uveal melanoma (UM). This study aimed to investigate and report the incidence and prognosis of UM in different regions of the world.

Methods: We retrieved relevant data on UM from the PubMed database and analyzed its global incidence and prognosis.

View Article and Find Full Text PDF

PDGFR-α shRNA-polyplex for uveal melanoma treatment via EMT mediated vasculogenic mimicry interfering.

J Nanobiotechnology

December 2024

National Engineering Research Center of Ophthalmology and Optometry, School of Biomedical Engineering, School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.

Up to 50% of individuals with uveal melanoma (UM), a frequent cancer of the eye, pass away from metastases. One of the major challenges in treating UM is the role of receptor tyrosine kinases (RTKs), which mediate the epithelial-mesenchymal transition (EMT) of tumors. RTKs are involved in binding multiple growth factors, leading to angiogenesis and vasculogenic mimicry (VM) phenomena.

View Article and Find Full Text PDF

Purpose: Uveal melanoma (UM) represents the most prevalent and aggressive intraocular malignancy in adults. This study examined the outcomes of patients diagnosed with high-risk UM who underwent fractionated stereotactic radiosurgery (fSRS) treatment utilizing a novel LINAC-based frameless technique.

Design: Retrospective, interventional case series.

View Article and Find Full Text PDF

The role of circulating tumor DNA in melanomas of the uveal tract.

Front Immunol

December 2024

Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Melanoma of the uveal tract or uveal melanoma (UM) originates from melanocytes of the eye and is the most common intraocular malignancy in adults. Despite considerable advances in diagnostic procedures and treatments, prognosis remains poor in those with advanced disease. Accordingly, although current treatments have an excellent local disease control rate, approximately 50% of patients develop metastatic relapse within 10 years.

View Article and Find Full Text PDF

Uveal melanoma is the most common primary eye cancer with the highest incidence. BEBIG Ru/Rh ophthalmic plaques more used for the treatment of these eye malignancies, mainly malignancies with small to medium sizes. In this study, we evaluate dose distributions around a voxelized eye phantom due to CCA and CCB eye plaque using GATE code.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!